Vivoryon pivots to kidney disease after Alzheimer's blow

10 December 2024

Vivoryon Therapeutics (Euronext: VVY) has announced Phase II data from its VIVA-MIND study of varoglutamstat, an investigational oral glutaminyl cyclase inhibitor.

The VIVA-MIND trial, conducted in the USA, failed to show significant efficacy in its primary endpoint, mirroring results from the earlier VIVIAD study in Europe.

Analysis showed no meaningful improvements in cognitive measures, aligning with disappointing data from the European trial that led to a 90% drop in Vivoryon’s share price earlier this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK